1. Home
  2. SCYX vs SYPR Comparison

SCYX vs SYPR Comparison

Compare SCYX & SYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • SYPR
  • Stock Information
  • Founded
  • SCYX 1999
  • SYPR 1997
  • Country
  • SCYX United States
  • SYPR United States
  • Employees
  • SCYX N/A
  • SYPR N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • SYPR Industrial Machinery/Components
  • Sector
  • SCYX Health Care
  • SYPR Industrials
  • Exchange
  • SCYX Nasdaq
  • SYPR Nasdaq
  • Market Cap
  • SCYX 50.3M
  • SYPR 52.5M
  • IPO Year
  • SCYX 2014
  • SYPR 1994
  • Fundamental
  • Price
  • SCYX $0.99
  • SYPR $1.93
  • Analyst Decision
  • SCYX Buy
  • SYPR
  • Analyst Count
  • SCYX 1
  • SYPR 0
  • Target Price
  • SCYX N/A
  • SYPR N/A
  • AVG Volume (30 Days)
  • SCYX 212.6K
  • SYPR 67.8K
  • Earning Date
  • SCYX 11-06-2024
  • SYPR 11-12-2024
  • Dividend Yield
  • SCYX N/A
  • SYPR N/A
  • EPS Growth
  • SCYX N/A
  • SYPR N/A
  • EPS
  • SCYX N/A
  • SYPR N/A
  • Revenue
  • SCYX $8,566,000.00
  • SYPR $141,466,000.00
  • Revenue This Year
  • SCYX N/A
  • SYPR N/A
  • Revenue Next Year
  • SCYX $405.82
  • SYPR N/A
  • P/E Ratio
  • SCYX N/A
  • SYPR N/A
  • Revenue Growth
  • SCYX N/A
  • SYPR 7.82
  • 52 Week Low
  • SCYX $0.90
  • SYPR $1.27
  • 52 Week High
  • SCYX $3.07
  • SYPR $2.93
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 30.44
  • SYPR 61.58
  • Support Level
  • SCYX $0.90
  • SYPR $1.84
  • Resistance Level
  • SCYX $1.25
  • SYPR $2.93
  • Average True Range (ATR)
  • SCYX 0.08
  • SYPR 0.24
  • MACD
  • SCYX -0.01
  • SYPR 0.04
  • Stochastic Oscillator
  • SCYX 23.54
  • SYPR 29.58

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About SYPR Sypris Solutions Inc.

Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics. The company offers a range of manufacturing, engineering, design, and other technical services. The business activity of the firm is functioned through Sypris Technologies and Sypris Electronics segments. Sypris Technologies segment is engaged in the sale of machined, welded, and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications whereas the Sypris Electronics segment is engaged in the sale of manufacturing services, technical services, and products to customers in the market for aerospace and defense electronics. Sypris derives the revenue from the Technologies segment.

Share on Social Networks: